Our results showed that compared to untreated tumors (group I), only PRL3-zumab treatment (group III) resulted in significant tumor suppression, whereas the other treatments (groups II, IV, V, and VI) lacked anti-tumor efficacy (Fig. 4b). This evidence concerns the gene PTP4A3 and neoplasm.